New ‘Star Wars' cancer treatment which pulverises tumours with sound waves
The NHS is set to become the only health system in Europe to use ground-breaking histotripsy technology, which removes the need for surgery by firing pulses to form micro bubbles from gases
A 'Star Wars' treatment which zaps hard-to-reach cancers using sound waves is being trialled on the NHS. The technology, called histotripsy, removes the need for surgery and instead fires pulses to form micro bubbles from gases within the tumour.
These 'bubble clouds' expand and contract in microseconds to destroy the cancer cells. The targeted ultrasound technology currently only available in the US will now be trialled by the NHS on liver cancer patients in Cambridge. If successful regulators say it will be a 'a major step forward' which it is hoped could be used to destroy pancreatic and kidney cancers.
The Government says Health Secretary Wes Streeting intervened to authorise controlled early access to the device, as part of a new Innovative Devices Access Pathway (ADIP) programme.
Mr Streeting, who previously had kidney cancer, told the Mirror: 'I've slashed red tape, so NHS patients will be the first in Europe to benefit from a revolutionary and non-invasive liver cancer treatment – that uses ultrasound technology to destroy tumours - years earlier than planned.
"Patients stand to see faster recovery times, fewer dangerous complications, and shorter hospital stays. We are slashing red tape, so game-changing new treatments reach the NHS front line quicker.'
In contrast to invasive surgery, the targeted ultrasound can take just 30 minutes with 'limited or no pain' and involves a quick recovery. It destroys tissue at cellular and sub-cellular levels while avoiding the ionising damage of radiation or the heat damage from thermal treatments.
The bubble clouds cause the cancerous mass to break apart, destroying tumor cells and leaving the debris to be eliminated by the immune system.
US cancer expert Dr Jennifer Linehan, of St John's Cancer Institute, said the device could in future also be used to pulverise prostate and bladder cancers. She said: 'This technology kills tumours without even touching you. Sometimes when I'm talking to patients I tell them this is ' Star Wars technology' because there are no cuts, there's no poking, there's nothing that's going inside you from outside. It's all happening with a focused beam of ultrasound to destroy the tumours.'
The first cancer patients in Europe to access the treatment under such a scheme will be treated for their liver cancer at Addenbrooke's Hospital in Cambridge this summer. The machine, manufactured by HistoSonics, is expected to be fully installed later this year, where it will be used initially to treat patients with primary and secondary liver tumours. Wider research on how this could potentially treat tumours in other organs is underway.
James Pound, innovation director at the Medicines and Healthcare products Regulatory Agency (MHRA), said: 'We've shown we can get promising technologies to patients faster without compromising safety. It's a major step forward for patients with liver cancer and shows how the UK can be a frontrunner in supporting responsible innovation that meets real clinical need.'
Patients undergoing histotripsy are given general anesthesia to control breathing and to minimize movements of targeted tumours An evaluation of the NHS pilot will be published later this year by the Department of Health and Social Care. Histotripsy has already been approved to treat liver tumors by the US Food and Drug Administration (FDA).
Roland Sinker, Chief Executive of Cambridge University Hospitals said: 'Histotripsy is an exciting new technology that will make a huge difference to patients. By offering this non-invasive, more targeted treatment we can care for more people as outpatients and free up time for surgeons to treat more complex cases.
'The faster recovery times mean patients will be able to return to their normal lives more quickly, which will also reduce pressure on hospital beds, helping us ensure that patients are able to receive the right treatment at the right time.'
Wes Streeting - Secretary of State for Health and Social Care
As a cancer survivor, I know what an incredible impact medical technology can have. After I was diagnosed with kidney cancer, I was treated by a world-class surgeon equipped with a robot. Together, they saved my life.
The NHS is abuzz with innovation and creativity. We're already witnessing the trial of an AI-driven blood test to spot common cancers, the roll-out of a game-changing system to bring cancer patients' data together, and the unprecedented expansion of the NHS app. It is my job to put the wind in the sails and give the world's greatest minds the freedom to unleash tomorrow's tech.
To strengthen Britain's role as a global leader, those innovators must be freed from the shackles of stifling regulatory processes. Of course, we need to keep patients safe, but technology is moving quickly, and so must we.
That's why I've already slashed red tape, so NHS patients will be the first in Europe to benefit from a revolutionary and non-invasive liver cancer treatment – developed by US-based company HistoSonics – that uses ultrasound technology to destroy tumours, years earlier than planned. Patients stand to see faster recovery times, fewer dangerous complications, and shorter hospital stays.
Soon, we will publish the 10 Year Health Plan – a once in a generation strategy to save and rebuild the NHS, delivering a health service fit for the future. This government will unleash innovation to speed the shift from analogue to digital, and tackle the bureaucracy holding back our public services
No longer will the creativity needed to bring our NHS into the modern age be stifled. Through our Plan for Change, we will get the latest tech to our NHS frontline, put patients first and develop a 21st century health service that's, once again, the envy of the world.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Rhyl Journal
36 minutes ago
- Rhyl Journal
Geologists unveil UK ‘super regions' with best potential for transition projects
The findings, published by the British Geological Survey (BGS), show the UK has an incredibly diverse subsurface, which can play a key role in supporting efforts to reach the country's legally binding climate goals. Many areas have geology that is well suited to certain net zero technologies, including shallow geothermal installations or critical minerals occurrences. But BGS scientists say eight super regions contain subsurface formations and conditions that are favourable to multiple different technologies within a relatively small area. These are Northern Ireland, the Scottish Central Belt, north-east England, north-west England, the South Yorkshire and Humber region, the East Midlands and East Anglia, South Wales and south-west England. Here, the subsurfaces can provide a sustainable heat source for geothermal energy, geological formations for secure storage of energy and carbon dioxide (CO2), rocks containing important resources for mineral extraction, and suitable geological foundation conditions for onshore and offshore wind infrastructure projects, the scientists said. For example, south-west England has significant deep geothermal resources offering opportunities for sustainable heat and power generation while its sedimentary basins provide potential sites for CCS and energy storage, they added. Meanwhile, the Scottish Central Belt boasts a complex geology, including sedimentary reservoir rocks and significant igneous intrusions, abundant geothermal resources, abandoned coal mines and a legacy of subsurface data, they said. The BGS said its findings offer crucial insights and a road map for decision makers, ministers and land managers looking to maximise return on investment in the energy transition. The geologists assessed that strategic spatial planning for such technologies in these areas can help unlock an estimated £40 billion of annual investment and support the Government's target of creating 650,000 jobs through renewable energy by 2030. But they added that further investigation will be required to fully establish each of the super region's true potential, ensure safe deployment of each technology, and understand environmental impact. Michelle Bentham, BGS chief scientist for decarbonisation and resource management, said: 'The UK is incredibly diverse in its geology. 'Because it's out of sight, geology gets a little bit forgotten about. 'And I don't think people realise how blessed we are in the UK, if you like, in terms of the geology that could really help us have a sustainable future. 'But you can really see the difference that geology could make to reaching Government goals in terms of net zero, energy provision, clean energy.' Ms Bentham said funding and the policy landscape may have been barriers to rolling out technologies such as CCS and geothermal energy across the UK. 'In Europe, geothermal energy is used much more widely. In the UK, we don't use it as widely and it's always been a bit of a Cinderella of clean energy technologies,' she said. 'And in the North Sea, we could potentially become a hub for carbon storage in Europe for countries that don't have the right geology who are trying to decarbonise,' she added. The BGS contributed to the consultation on the Government's upcoming land use framework, which looks at how England's finite land can meet the escalating demands of food security, clean energy, nature restoration and new homes. But the framework is focusing more on surface demands, with some scope for shallow subsurface areas such as geothermal infrastructure. Ms Bentham said strategic spatial planning for the subsurface could also help optimise the UK's resources for the energy transition. For example, it could stop decision makers from locking into one technology – such as wind farms or CCS – in one area where another could have yielded more benefits, or where multiple technologies could have been deployed. 'Like the map, it's not one technology that's going to be the answer,' she said. 'That's why we need this combination to give us flexibility.' The BGS highlighted that the data underpinning its research has been shaped by geologists' current understanding of the subsurface, adding that a few parts of the country have been less extensively surveyed than others, and more research is required to fully assess their potential.
South Wales Argus
2 hours ago
- South Wales Argus
Dentists slam Welsh Government's NHS dental reforms
The British Dental Association Cymru has warned the Welsh Government that the changes could lead to an exodus from the workforce and should be paused for further trials. The proposed reforms aim to improve oral health, increase prevention, and provide better value for money. However, a survey indicates that only two per cent of dentists believe the changes will support NHS dentistry's sustainability. Just five per cent agree the reforms will enhance prevention, and eight per cent think they will improve access to NHS care. A significant concern is the shift in patient appointments to up to 24 months apart, which could limit early disease detection, including oral cancers. The changes also propose moving patients to a centralised database, potentially fragmenting family care. The reforms are expected to be introduced next year.
North Wales Chronicle
3 hours ago
- North Wales Chronicle
Women with genetic cancer risk being ‘missed' due to testing gaps
A lack of testing for Lynch syndrome also means some cancer patients are unaware of their risk of developing other cancers, academics said. Lynch syndrome is a rare condition which runs in families which puts people at a higher risk of developing cancers of the bowel, womb and ovaries. It is caused by a mutation in the gene that fixes mistakes in DNA when it is copied, which can lead to uncontrolled cell growth. Patients with bowel or womb cancer should have their tumours assessed for markers of Lynch syndrome, according to guidance for the NHS. If these markers are identified, patients should be referred for genetic testing so the diagnosis can be confirmed and they can get support and advice about cancer risk for themselves and their family. A new study by academics at the University of Edinburgh found not all womb cancer patients are being sent for genetic testing. Researchers examined data on 2,500 womb cancer patients across the UK and Ireland between 2022 and 2023. We have launched a Guide to #LynchSyndrome to help provide information and support to anyone who thinks they may have it, that it may run in the family, or have found out they have — The Eve Appeal (@eveappeal) February 13, 2023 They found that 91% of tumours were tested for markers of Lynch syndrome, but the test results were not routinely communicated to the wider clinical team. This means that follow-up genetic counselling and blood tests were not always arranged. Of the 181 participants eligible for genetic counselling, just under two-thirds (64%) were referred for appointments, according to the study, which has been published in the journal BMJ Oncology. Researchers said those who were referred faced long waits, resulting in high dropout rates, meaning only 48% of those eligible went on to get the test. Today's #LynchSyndromeAwarenessDay. Our policy team sat down with our supporter, Jane, to share her experience. As well as highlighting what else needs to be done to improve Lynch syndrome care. Read our blog: — Bowel Cancer UK (@bowelcanceruk) March 22, 2025 Experts from the university said gaps in testing mean some womb cancer patients with Lynch syndrome go undetected. Family members are also left vulnerable to cancer risk, unaware they may have the condition. Dr Neil Ryan, from the University of Edinburgh, who leads the UK audit and research collaborative in obstetrics and gynaecology, said: 'Despite clear guidance and excellent rates of tumour testing, too many women with Lynch syndrome are still being missed because they're not referred for definitive blood testing in a timely way. 'This not only denies them the chance to reduce their future cancer risk but also prevents their relatives from being tested and protected. 'Tumour testing is only cost-effective if it leads to diagnosis — we urgently need to make mainstream testing truly mainstream.'
